retifanlimab,pembrolizumab,Bria-IMT
Incyte,Merck,BriaCell Therapeutics
['briacell', '$bctx']
$bctx remember when briacell first showed survivor benefit in june 2021, it was 12-21 months v overall survival rate of 7-10 mo. at #aacr23 $bctx showed further increased benefit. 15 of 18 patients are still alive from study, so now survival benefit is ~33-45 months! 
Organic and Biochemistry, Whisky Enthusiast.  Find undervalued biotech and resource related companies and take large positions to hold.